GLYCOLIPID COMPOUNDS AND THEIR USES IN THE TREATMENT OF TUMOURS
The invention relates to novel glycolipid compounds and pharmaceutical compositions comprising said glycolipids and to processes for preparing said glycolipids. The invention also relates to said glycolipids for use in treating tumours and methods of treating tumours using said glycolipids.
1 . A glycolipid compound selected from a compound of formula (I), (II) and (III) or a pharmaceutically acceptable salt thereof:
2 . A pharmaceutical composition comprising the glycolipid compound or a pharmaceutically acceptable salt thereof as defined in claim 1 .
3 . A method for treating a tumour in a subject comprising administering the pharmaceutical composition as defined in claim 2 .
4 . The method as defined in claim 3 , wherein the tumour is a solid tumour, myeloma, or a lymphoma.
5 . The method as defined in claim 3 , wherein the tumour is a tumour originating from an organ selected from peritoneum, liver, pancreas, lung, urinary bladder, prostate, uterus, cervix, vagina, bone marrow, breast, skin, brain, lymph node, head and neck, stomach, intestine, colon, kidney, testis, and ovaries.
6 . The method as defined in claim 3 , wherein the tumour comprises a primary tumour and/or a metastasis.
7 . The method as defined in claim 3 , wherein the tumour comprises melanoma, sarcoma, glioma, or carcinoma cells.
8 . The method as defined in claim 3 , wherein the administering is by injection.
9 . The method as defined in claim 3 , wherein the administering is by one dose or multiple doses.
10 . The method as defined in claim 3 , wherein the administering step comprises administration by topical application.
11 . The method as defined in claim 3 , wherein the pharmaceutical composition additionally comprises one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s).
12 . The method as defined in claim 3 , wherein the pharmaceutical composition additionally comprises one or more additional therapeutic agents.
13 . The method as defined in claim 12 , wherein the one or more additional therapeutic agents comprise one or more systemic inhibitors of immune system down-regulation, such as anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies, in particular anti-PD-1 antibodies.
14 . A method of treating a tumour in a subject, comprising:
a) providing:
i) a subject comprising at least one tumour that comprises a plurality of cancer cells having a cell surface; and
ii) the pharmaceutical composition as defined in claim 2 ; and
b) introducing said glycolipid or composition into the tumour.
15 . The method as defined in claim 14 , wherein the subject is a human or a mouse.
16 . The method as defined in claim 14 , wherein the introducing step comprises a procedure selected from: injection, imaging guided injection, endoscopy, bronchoscopy, cystoscopy, colonoscopy, laparoscopy, and catheterization.
17 . The method as defined in claim 14 , which additionally comprises inducing an intratumoural inflammation.
18 . The method as defined in claim 14 , wherein the subject was treated previously to surgically remove the tumour.
19 . The method as defined in claim 14 , wherein the subject was not treated previously to remove the tumour.
20 . The method as defined in claim 14 , wherein the tumour undergoes regression or is destroyed.
21 . The method as defined in claim 14 , wherein the introducing step further comprises regression or destruction of a second tumour in the subject.
22 . The method as defined in claim 10 , wherein the composition is a topical ointment, topical lotion or topical solution.